ANDA 218792, held by Sandoz Inc. Upadacitinib.
As of Nov 15, 2026, ANDA 218792 (Upadacitinib), held by Sandoz Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 14, 2025 | Original application | Tentative approval | None posted |
| Upadacitinib30MG · tablet, extended release | Upadacitinib | None (tentative approval) |
| Upadacitinib15MG · tablet, extended release | Upadacitinib | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters